Metabolic risks remain largely unmonitored in Medicaid patients taking antipsychotics
Monday, January 4, 2010 - 21:14
in Health & Medicine
Despite government warnings and professional recommendations about diabetes risks associated with second-generation antipsychotic drugs, fewer than one-third of Medicaid patients who are treated with these medications undergo tests of blood glucose or lipid levels, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.